Skip to main content

This Dividend Stock Has Plunged Ahead of Trump’s Inauguration. Here Are 3 Reasons Investors Should Still Buy It.


The stock market has experienced significant shifts following Donald Trump’s election, as investors reposition their portfolios in anticipation of the new administration's policies. One sector that has been particularly affected is pharmaceuticals and healthcare, which was already facing downward pressure. This decline continued after President-elect Trump nominated Robert F. Kennedy, Jr. to lead the Department of Health and Human Services (HHS).

Kennedy, a known vaccine skeptic, triggered a market reaction that led to a selloff in vaccine manufacturers, including pharmaceutical giant Pfizer (NYSE: PFE). After falling 10% in 2022 and 41% in 2023, Pfizer ended 2024 with a 2% decline, trading around $26 per share. Given its multi-year low, many investors are questioning whether now is the right time to buy or sell Pfizer stock as Trump’s inauguration approaches. In this article, we’ll examine the reasons behind Pfizer’s price drop and why it may still be a compelling investment.

Why Is Pfizer Stock So Low?

1. Declining COVID-19-Related Sales

During the pandemic, Pfizer became a household name thanks to its COVID-19 vaccine and antiviral pill, Paxlovid. These products generated unprecedented revenue, pushing PFE stock to record highs. However, as the world moved past the pandemic, demand for these treatments plummeted. Consequently, Pfizer’s sales dropped, dragging its stock price down as well.

The company's once-booming COVID-19 portfolio is no longer a major revenue driver, and analysts expect continued declines in pandemic-related sales. Despite these challenges, Pfizer has been investing heavily in other therapeutic areas, particularly oncology, to diversify its revenue streams.

2. Pipeline Setbacks and Patent Expirations

Another factor weighing on Pfizer’s stock price is the mixed success of its drug pipeline. In December 2023, the company halted the development of danuglipron, its twice-daily oral weight-loss drug, due to adverse side effects. Given the explosive growth of the weight-loss drug market, particularly with GLP-1 receptor agonists from Novo Nordisk (NVO) and Eli Lilly (LLY), this was a significant setback for Pfizer.

Adding to investor concerns, several key Pfizer drug patents are set to expire within the next five years. Patent expirations mean increased competition from generic drugmakers, putting pressure on revenue and profit margins. The company must successfully launch new drugs to compensate for these upcoming revenue losses.

3. Seagen Acquisition and Increased Debt

Pfizer’s recent $43 billion acquisition of Seagen, a biotechnology firm specializing in cancer treatments, was met with skepticism from investors. The deal added substantial debt to Pfizer’s balance sheet, raising questions about the company’s ability to generate sufficient returns on this investment.

Despite the concerns, Seagen’s oncology treatments align well with Pfizer’s long-term strategy. If managed effectively, the acquisition could strengthen Pfizer’s position in the growing cancer treatment market and contribute significantly to future revenues.

Pfizer Stock Forecast

Wall Street analysts remain divided on Pfizer’s future. Out of 24 analysts covering PFE:

  • 11 rate it as a “Strong Buy”

  • 12 rate it as a “Hold”

  • 1 rates it as a “Strong Sell”

The average price target for PFE is $31.33, representing a 19.5% upside from its recent trading price. Some bullish analysts have set a high-end target of $45, implying a potential gain of 71.6%.

Meanwhile, UBS remains cautious about pharmaceutical stocks ahead of Trump’s inauguration. The firm recently lowered its price target on Pfizer to $29 and described 2025 as a "transition year" for the company. UBS analysts believe uncertainty surrounding Trump’s healthcare policies could weigh on the sector in the near term.

3 Reasons to Buy Pfizer Stock Now

While PFE has struggled in recent years, several factors suggest that it remains a solid long-term investment. Here are three key reasons why investors should consider buying Pfizer stock despite its recent declines.

1. Expansion in Oncology and Seagen’s Growth Potential

Cancer treatments represent a lucrative and rapidly expanding segment of the pharmaceutical industry. With its Seagen acquisition, Pfizer is making a strong push into oncology, a strategic move that could pay off in the long run. The company expects Seagen to contribute $10 billion in risk-adjusted sales by the end of the decade.

Pfizer’s broader oncology portfolio already includes blockbuster drugs like Ibrance, Xtandi, and Lorbrena. These products, combined with Seagen’s cutting-edge antibody-drug conjugates (ADCs), position Pfizer as a leader in cancer therapeutics. If the company successfully executes its oncology strategy, it could unlock significant value for shareholders.

2. Attractive Valuation and Low Price-to-Earnings (P/E) Ratio

Pfizer currently trades at a P/E ratio of less than 10 based on forward earnings. This valuation is significantly lower than the broader pharmaceutical industry average, making Pfizer an attractive option for value investors.

Although earnings are expected to decline in the short term, analysts anticipate a recovery in the coming years. If Pfizer can stabilize its revenues through new product launches and cost-cutting initiatives, its stock price could rebound significantly.

3. High Dividend Yield and Reliable Payouts

For income-focused investors, Pfizer’s dividend yield of over 6.5% is a compelling reason to hold the stock. The company has a strong history of paying dividends and has consistently returned capital to shareholders through dividend payouts and share buybacks.

Despite recent struggles, Pfizer’s cash flows remain healthy enough to sustain its dividend payments. In a volatile market environment, high-yield dividend stocks like Pfizer provide investors with a steady stream of passive income, helping to offset stock price fluctuations.

Conclusion: Should You Buy Pfizer Stock?

Pfizer faces several near-term challenges, including declining COVID-19-related sales, patent expirations, and debt from the Seagen acquisition. However, its focus on oncology, attractive valuation, and strong dividend yield make it a compelling long-term investment.

While investors should brace for potential volatility, those with a long-term perspective may find Pfizer to be a worthwhile addition to their portfolios. The stock’s current low valuation, combined with a promising oncology pipeline and a robust dividend, make it a solid pick for both growth and income investors.

As with any investment, it’s important to conduct your own research and consider your risk tolerance before making a decision. While Pfizer may not be a short-term winner, its long-term prospects remain promising for patient investors willing to ride out near-term uncertainty.

Disclaimer: The information provided in this article is for informational purposes only and should not be considered financial advice. Investors should conduct their own due diligence before making any investment decisions.

Comments

👀 Black Friday finds worth checking out! I spotted some fun, affordable finds on Temu that caught my eye! If you’re new to Temu, don’t miss the chance to discover your next favorite find. 🎁 You can search alq912051 in the Temu App to find the deals or check them out here: Happy deal hunting! #TemuFinds #BlackFriday

Popular posts from this blog

GPIQ Is The Clear Outperformer Over JEPQ: A Multi-Criteria Comparison

Investors seeking income and growth from Nasdaq-100 exposure have two popular ETF choices: GPIQ (Goldman Sachs Nasdaq-100 Core Premium Income ETF) and JEPQ (JPMorgan Nasdaq Equity Premium Income ETF). Both tap into premium-income strategies, but after digging into the data, GPIQ emerges as the better performer on several fronts. Here’s why. What Are These Funds & How They Differ ETF Strategy & Key Attributes GPIQ Managed by Goldman Sachs; uses a covered-call (option overlay) strategy (writing calls on portions of its Nasdaq-100 exposure), dynamic in how much is “overlaid,” aiming for income + participation in upside. StockAnalysis +3 AInvest +3 PortfoliosLab +3 JEPQ Managed by JPMorgan; uses equity-linked notes (ELNs) and derivative structures, plus underlying Nasdaq-100 equity exposure. High yield tends to come with trade-offs in flexibility and cost. Tickeron +3 AInvest +3 StockAnalysis +3 Criteria: How GPIQ Outperforms Below are the main axes of comparison, and how ...

SCHD vs. VIG: Which One Is Better?

When it comes to dividend growth ETFs, two heavyweights constantly show up in investor conversations: Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Dividend Appreciation ETF (VIG) . Both funds focus on companies with strong dividend-paying track records, but they take very different approaches. The result? Distinct performance profiles, yield expectations, and suitability depending on your goals. This blog takes a deep dive into both ETFs, comparing their strategies, holdings, performance, fees, and ideal investor profiles to answer the big question: Which one is better—SCHD or VIG? 1. The Basics Before we get lost in the weeds, let’s start with the core facts. SCHD (Schwab U.S. Dividend Equity ETF) Launch: 2011 Index: Dow Jones U.S. Dividend 100 Index Holdings: ~100 companies Expense Ratio: 0.06% Focus: High-quality U.S. dividend stocks with a strong yield + sustainability screen. Dividend Yield (2025): ~3.5–4.0% VIG (Vanguard Dividend Appre...

Nvidia Earnings Preview: Data Centers, Margins, and the Great AI Spending Test

Nvidia is scheduled to report its second-quarter fiscal 2027 results on August 26, 2026, and I have reached the point where describing one of its earnings reports as “highly anticipated” feels almost comically inadequate. The market does not merely wait for Nvidia’s numbers anymore. It gathers around them like anxious relatives outside a delivery room. An ordinary company reports revenue, earnings and guidance. Nvidia reports the current condition of the artificial-intelligence economy. Its results influence semiconductor stocks, cloud providers, electrical-equipment companies, data-center developers, utilities and nearly every business that has managed to place the letters “AI” somewhere in an investor presentation. If Nvidia beats expectations, optimism spreads across the market as though the company has personally confirmed that the future remains under warranty. If management offers one cautious sentence about supply, margins or deployment timing, investors begin examining it with ...